Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications - Wikidata - awgldk - TriplyDB

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

http://www.wikidata.org/entity/Q34805283

about

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina.Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.Fabry disease: multidisciplinary evaluation after 10 years of treatment with agalsidase Beta.Continuous cardiac troponin I release in Fabry disease Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa.Innate and Adaptive Immune Response in Fabry Disease Quality of life in patients with Fabry disease: a systematic review of the literature.Cardiac Troponin I: A Valuable Biomarker Indicating the Cardiac Involvement in Fabry Disease.Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.Fibrosis: a key feature of Fabry disease with potential therapeutic implications Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease Fabry disease: a rare cause of neuropathic pain.Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.Treatment of lysosomal storage disorders: successes and challenges.Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.Human-Induced Pluripotent Stem Cell-Based Modeling of Cardiac Storage Disorders.Ultra-orphan diseases: a quantitative analysis of the natural history of molybdenum cofactor deficiency.Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study.Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease.Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST).GLA mutation as a risk factor for later life small vessel ischaemic disease.Biomarkers in Lysosomal Storage Diseases Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study.E-Learning for Rare Diseases: An Example Using Fabry Disease.Severe hypertrophic cardiomyopathy in a patient with atypical Anderson-Fabry disease.Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.

P2860

Q31060724-4E4310A9-D542-4D72-BF0C-7F6DAC3F9CBA Q33645550-516B7774-72A2-4655-A16E-B598BDE362AE Q33652370-10608EB4-97D2-4484-8CCF-B99592CC55DD Q33776219-A1DB772B-2CDD-445F-BD95-A0AC239A4A14 Q33886219-1BEF25CD-74DE-41CA-9963-05187C4BC41B Q34457667-A61950F7-C62E-40E4-BBEC-FFFB73BDEF40 Q35120187-D85199B9-02B5-4F3E-B5C8-399D32C68A44 Q35247511-22334EEE-04D5-471C-A8F8-2BD562DDF3C4 Q35550696-07E80D5C-4E25-4ADC-811A-DD32E60442AE Q35795427-283AF6EF-3B65-46EE-BC42-13AB7733243E Q35800976-D538014C-78C3-4E5B-BD90-030FA6E69EB5 Q35849151-86D586E4-E33F-48E8-A805-DF23669F571D Q36056601-05DE406A-F03B-4866-866A-177277522E7C Q36105190-46F0F687-13C5-437E-AA80-0D081ADE825A Q36213022-56E53ADF-5F95-46F3-973F-C3A4F54FADC7 Q36309032-CAB9F4F8-B3BC-47B2-BA80-44B4C3B3C817 Q36475780-F30C4083-431E-41E1-8319-216998F5CEFF Q36571559-3CED5720-AFFB-427C-AEFE-D0C00AEE7F74 Q37054755-37AB0159-57A5-4A01-A307-F75BB37CE5DC Q37113004-2FFD4462-BE77-4D65-9573-CCFC6C257F7A Q37624954-90854116-5063-438A-B7F1-FBE57D4240E6 Q38133441-033D9EEB-9839-4F6D-8147-8E144722FB93 Q38184922-9C52EFE1-7A12-4717-9DFC-948BFADD8D42 Q38211269-A7004BE7-ECEA-492A-A2B2-FAA3E974CC92 Q38230252-BC74634C-5E74-4021-BBF4-86B107F50D61 Q38751652-A2491944-48DC-4FB3-82AC-D2E91C45501F Q39030078-25930CF1-A275-4C3C-AD9F-BF9DE54647E6 Q39097273-8C706C54-2E62-407A-A4BD-6E5C0B3608C6 Q39344648-7DE30AA4-C0EE-4BB0-99CC-5D519886ADAE Q41200738-0ABFDEF3-6909-4DCB-8E55-9FEE282E0739 Q41562385-CAFB3B98-D923-4F2B-9376-14C5368FAEE0 Q41856965-423666B9-8627-4FB0-8131-D68EC16740BC Q42226765-D1CDA25A-CB3A-4D4C-A83A-97F228500AC1 Q46881710-92916FB4-27D7-446E-BE5D-F4FDB4610071 Q47147113-54F7D09E-76EE-460E-AB60-2B3EF1B69A1C Q47935620-26021173-55EF-4C12-A709-BBED9A6A53CF Q48091189-51E7851D-A982-4549-BDF4-60BF50929D95 Q48254826-5CC7D5F1-4214-413D-A444-3112C2F465E4 Q49548756-7B97085B-E288-46D1-AB47-B0A9522606E5 Q50043588-456B9B2A-5DE2-4111-B5F7-1F4903ACBD10

P2860

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

http://www.wikidata.org/entity/Q34805283

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Long-term outcome of enzyme-re ...... towards serious complications

@ast

Long-term outcome of enzyme-re ...... towards serious complications

@en

Long-term outcome of enzyme-re ...... towards serious complications

@nl

type

label

Long-term outcome of enzyme-re ...... towards serious complications

@ast

Long-term outcome of enzyme-re ...... towards serious complications

@en

Long-term outcome of enzyme-re ...... towards serious complications

@nl

prefLabel

Long-term outcome of enzyme-re ...... towards serious complications

@ast

Long-term outcome of enzyme-re ...... towards serious complications

@en

Long-term outcome of enzyme-re ...... towards serious complications

@nl

P1433

Q34805283-0226C036-1E5D-4E75-941C-AAD0A0D10E22

P1476

Q34805283-242EAD5E-0A7E-49F7-BB48-6B83630B046A

P2093

Q34805283-0A13CD9E-6B15-40FB-BC80-0C7E1BFA3F14

Q34805283-3ACBCF63-5988-4C25-A674-865E1DC80F87

Q34805283-4F05929C-B03C-4D30-8274-F70B67E5FA82

Q34805283-84810A53-120E-4907-AB69-3D8C91A987EB

Q34805283-8FAD617B-2D10-4847-B059-6F813FB6EB74

Q34805283-906C0016-83FA-4847-9E6A-5A2B91F4AB6C

Q34805283-95CE0E3B-222E-432A-86D5-E07D978071B3

Q34805283-B97CD03D-6C6F-4A69-8BE8-4EB4A0DA9373

Q34805283-E4644FB6-B66A-4759-BFA4-6742CAD4507A

P2860

Q34805283-0A66C3BF-CC03-44B8-B1E3-DF68D8804805

Q34805283-0ABC1B48-7A41-4D51-B9A2-BAF0D6D71A2F

Q34805283-15AAB827-7F9D-4C49-8CF9-027EE1D0B253

Q34805283-27617141-598C-46C6-AB96-9F2C6535DEFA

Q34805283-2B9B888B-AC64-41AA-B07C-33905C6737CD

Q34805283-2FA86739-2A6E-45F0-B448-8214E6A2E2E6

Q34805283-4042DA10-C6CF-4264-9F33-5BA73F0076FB

Q34805283-4383A7B4-9653-4DEE-AE5D-A50BB8CF050B

Q34805283-614C3435-5DDC-405F-8C03-07D4BA414869

Q34805283-6EE2EACD-7EDF-4BB6-9F21-1EFE37C40523

P304

Q34805283-ABE0B85A-129F-42A7-A8D5-28477789C56B

P31

Q34805283-4858AB4D-7E77-4ECB-BFF3-6C28D0EF3105

P356

Q34805283-A03749C8-493C-4410-810C-3605E6D4C86D

P407

Q34805283-C553B336-A366-4B8B-98F9-11976DE22702

P433

Q34805283-126F6FEA-7814-4D24-815E-9FC3AF948286

P478

Q34805283-5DB1ED51-233B-40C4-BD63-DD18EE719D8A

P577

Q34805283-CDF37895-3C13-48A8-A007-BEF7729B9BAD

P5875

Q34805283-749E9B13-9965-4A56-A75E-2C19E89134A3

P698

Q34805283-56C723AC-AB78-4880-B1BD-2A26DD4F7AE1

P921

Q34805283-6FCEB76B-BA22-43BB-8B73-7191D2E73252

P932

Q34805283-335F6FF2-8FEB-49A8-9BA3-0CBECB3DD1CA

P356

P1433

Journal of Internal Medicine

P1476

Long-term outcome of enzyme-re ...... towards serious complications

@en

P2093

C Sommer

http://www.w3.org/2001/XMLSchema#string

C Wanner

http://www.w3.org/2001/XMLSchema#string

F Breunig

http://www.w3.org/2001/XMLSchema#string

F Weidemann

http://www.w3.org/2001/XMLSchema#string

G Ertl

http://www.w3.org/2001/XMLSchema#string

M Beer

http://www.w3.org/2001/XMLSchema#string

M Niemann

http://www.w3.org/2001/XMLSchema#string

S Herrmann

http://www.w3.org/2001/XMLSchema#string

S Störk

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Cardiovascular events in patients with fabry disease natural history data from the fabry registry.

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.

Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

P304

331-341

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JOIM.12077

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

274

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236183491

http://www.w3.org/2001/XMLSchema#string

P698

23586858

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy

P932

4282332

http://www.w3.org/2001/XMLSchema#string